| 000 | 02515 a2200637 4500 | ||
|---|---|---|---|
| 005 | 20250516071908.0 | ||
| 264 | 0 | _c20120330 | |
| 008 | 201203s 0 0 eng d | ||
| 022 | _a1527-7755 | ||
| 024 | 7 |
_a10.1200/JCO.2011.38.2614 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSubbiah, Vivek | |
| 245 | 0 | 0 |
_aTreatment of patients with advanced neurofibromatosis type 2 with novel molecularly targeted therapies: from bench to bedside. _h[electronic resource] |
| 260 |
_bJournal of clinical oncology : official journal of the American Society of Clinical Oncology _cFeb 2012 |
||
| 300 |
_ae64-8 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAngiogenesis Inhibitors _xtherapeutic use |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal, Humanized _xadministration & dosage |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadverse effects |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
| 650 | 0 | 4 |
_aBenzenesulfonates _xadministration & dosage |
| 650 | 0 | 4 | _aBevacizumab |
| 650 | 0 | 4 | _aChild |
| 650 | 0 | 4 | _aChild, Preschool |
| 650 | 0 | 4 | _aDrug Synergism |
| 650 | 0 | 4 | _aErlotinib Hydrochloride |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aIndoles _xadministration & dosage |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMolecular Targeted Therapy _xmethods |
| 650 | 0 | 4 |
_aNeurofibromatosis 2 _xdrug therapy |
| 650 | 0 | 4 |
_aNiacinamide _xanalogs & derivatives |
| 650 | 0 | 4 | _aPhenylurea Compounds |
| 650 | 0 | 4 |
_aPyridines _xadministration & dosage |
| 650 | 0 | 4 |
_aPyrroles _xadministration & dosage |
| 650 | 0 | 4 |
_aQuinazolines _xadministration & dosage |
| 650 | 0 | 4 |
_aSirolimus _xadministration & dosage |
| 650 | 0 | 4 | _aSorafenib |
| 650 | 0 | 4 | _aSunitinib |
| 650 | 0 | 4 |
_aTOR Serine-Threonine Kinases _xantagonists & inhibitors |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aValproic Acid _xadministration & dosage |
| 650 | 0 | 4 |
_aVascular Endothelial Growth Factor A _xantagonists & inhibitors |
| 650 | 0 | 4 | _aYoung Adult |
| 700 | 1 | _aSlopis, John | |
| 700 | 1 | _aHong, David S | |
| 700 | 1 | _aKetonen, Leena M | |
| 700 | 1 | _aHamilton, Jackson | |
| 700 | 1 | _aMcCutcheon, Ian E | |
| 700 | 1 | _aKurzrock, Razelle | |
| 773 | 0 |
_tJournal of clinical oncology : official journal of the American Society of Clinical Oncology _gvol. 30 _gno. 5 _gp. e64-8 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1200/JCO.2011.38.2614 _zAvailable from publisher's website |
| 999 |
_c21423135 _d21423135 |
||